This corrects the article DOI: 10.1038/nrneph.2017.155.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrneph.2017.175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing Long-Term Outcomes in Glomerular Disease Patients Presenting with Nephrotic Syndrome Versus Nephrotic Range Proteinuria.
Life (Basel)
December 2024
Department of Nephrology, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Background: Despite extensive research on proteinuria's impact on chronic kidney disease progression, there is no direct comparison of outcomes in biopsy-diagnosed glomerular disease (GD) patients with nephrotic syndrome (NS) or nephrotic range proteinuria (NRP). Our study addresses this gap, comparing long-term outcomes between NS and NRP.
Methods: We conducted a retrospective study on 240 kidney biopsy-proven GD patients, tracked from 2010 to 2015 until end-stage kidney disease (ESKD), death, or the study end in January 2022.
Nephrotic syndrome induces the upregulation of cell proliferation-related genes in tubular cells in mice.
Clin Exp Nephrol
December 2024
Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi, Chuo-ku, Niigata, 951-8510, Japan.
Background: Massive proteinuria, dyslipidemia, and hypoalbuminemia induced by nephrotic syndrome (NS) secondarily affect tubular cells. We conducted an RNA sequencing (RNA-seq) analysis using a mouse model of focal segmental glomerulosclerosis to clarify the impact of NS on tubular cells.
Methods: We used transgenic mice expressing hCD25 in podocytes (Nep25) to induce NS by injecting human CD25-specific immunotoxin (LMB2) at a dose of 0.
Complex dyslipidemia induced by Lorlatinib therapy: A case study.
J Clin Lipidol
October 2024
Section of Nutrition and Metabolic Diseases, Division of Endocrinology, Department of Internal Medicine and the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Context: Lorlatinib is an anaplastic lymphoma kinase (ALK) inhibitor, which is currently used for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Previous reports have noticed an association between lorlatinib and hyperlipidemia, however the specific mechanisms for this side effect remain unknown. Some investigators have reported nephrotic syndrome to be the underlying cause of lorlatinib-induced hyperlipidemia.
View Article and Find Full Text PDFFenofibrate in Lipoprotein Glomerulopathy: A 20-Year Long Resolution.
Int J Surg Pathol
November 2024
Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias. Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Activation of the inflammasome and pyroptosis cascade in podocytes of patients with minimal change disease.
Clin Kidney J
August 2024
Department of Anatomy, Showa University School of Medicine, Tokyo, Japan.
Background: In contrast to childhood minimal change disease (MCD), adult-onset MCD frequently recurs and requires prolonged immunosuppressive therapy. Accordingly, an investigation of the pathogenesis of adult MCD is required. MCD is usually accompanied by severe dyslipidaemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!